From: < @nhs.scot>

**Sent:** 28 January 2022 10:29

To: @novartis.com>

Subject: RE: Fingolimod Price - Novartis

Sure, no problem

National Procurement
Procurement, Commissioning, Facilities

# **NHS National Services Scotland**

2 Swinhill Avenue Canderside Toll Larkhall ML9 2QX

T: M: F:

E: @nhs.scot https://www.nss.nhs.scot/

Please consider the environment before printing this email.

NHS National Services Scotland is the common name for the Common Services

Agency for the Scottish Health Service. www.nhsnss.org

From: < <u>@novartis.com</u>>

**Sent:** 28 January 2022 10:24

To: \_\_\_\_\_\_ < \_\_\_\_\_\_ @nhs.scot>
Subject: RE: Fingolimod Price - Novartis

HI

Sorry – I'm in a meeting, will call you back before 2pm if that's OK?

Thanks

From: < <u>@nhs.scot</u>>

**Sent:** 28 January 2022 10:13

To: <u>@novartis.com</u>>

Subject: RE: Fingolimod Price - Novartis

This Message is from an External Sender. Do not click links or open attachments unless you trust the sender.

Hi

Apologies for late reply. I was trying to call you few minutes ago. I am working until 2pm if you need to talk.

#### Thanks

National Procurement
Procurement, Commissioning, Facilities

## **NHS National Services Scotland**

2 Swinhill Avenue Canderside Toll Larkhall ML9 2QX

T:
M:
F:
E: @nhs.scot
https://www.nss.nhs.scot/

Please consider the environment before printing this email.

NHS National Services Scotland is the common name for the Common Services Agency for the Scottish Health Service. <a href="https://www.nhsnss.org">www.nhsnss.org</a>

From: <u>@novartis.com</u>>

**Sent:** 21 January 2022 11:02

Hi

Happy New year to you.

I don't suppose you have 5 mins spare for a quick catch up on Monday do you?

## **Thanks**



From: @nhs.scot>

Sent: 22 December 2021 14:14

To: <a href="mailto:quanto:com"> quantities.com</a>

Subject: RE: Fingolimod Price - Novartis

This Message is from an External Sender. Do not click links or open attachments unless you trust the sender.

Hi you can call me anytime today. I am planning to work until 4pm. Thanks

National Procurement
Procurement, Commissioning, Facilities

## **NHS National Services Scotland**

2 Swinhill Avenue Canderside Toll Larkhall ML9 2QX

T: M: F:

E: @nhs.scot https://www.nss.nhs.scot/

Please consider the environment before printing this email.

NHS National Services Scotland is the common name for the Common Services

Agency for the Scottish Health Service. www.nhsnss.org

From: <u>@novartis.com</u>>

Sent: 22 December 2021 14:01

Hi

Would 1400 work?

From: < <u>@nhs.scot</u>>

Sent: 22 December 2021 13:14

To: <a href="mailto:quanto:com"> quantities.com</a>

**Subject:** RE: Fingolimod Price - Novartis

This Message is from an External Sender. Do not click links or open attachments unless you trust the sender.

Yes of course, can you please tell me what time are you free? We can either contact via Teams or mobile.

Thank you

National Procurement
Procurement, Commissioning, Facilities

#### **NHS National Services Scotland**

2 Swinhill Avenue Canderside Toll Larkhall ML9 2QX



Please consider the environment before printing this email.

NHS National Services Scotland is the common name for the Common Services

Agency for the Scottish Health Service. www.nhsnss.org


From: @novartis.com>
Sent: 22 December 2021 08:56
To: @nhs.scot
Subject: RE: Fingolimod Price - Novartis

Hi

Sorry – I was on annual leave yesterday.

Shall we have a quick call today if you are free?

**Thanks** 



This Message is from an External Sender. Do not click links or open attachments unless you trust the sender.

Yes, please that would be great.

Have a nice weekend.



, National Procurement Procurement, Commissioning, Facilities

# **NHS National Services Scotland**


2 Swinhill Avenue Canderside Toll Larkhall ML9 2QX

T:
M:
F:
E: @nhs.scot
https://www.nss.nhs.scot/

Please consider the environment before printing this email.

NHS National Services Scotland is the common name for the Common Services

Agency for the Scottish Health Service. www.nhsnss.org



Can I come back to you next week on this?

# Thanks



This Message is from an External Sender. Do not click links or open attachments unless you trust the sender.

I hope you are both well.

To follow up our recent catch up (23 November 2021) on the Fingolimod (Gilenya®) I would be grateful if you could clarify Novartis pricing strategy – is Novartis planning to reduce prices on Fingolimod products?

I understand that there is a Patent Access Scheme (PAS) in place since 2019 and I would like to understand if Novartis's tendering prices will be lower than current PAS prices?

I would be grateful for your prompt response.

Thank you

National Procurement
Procurement, Commissioning, Facilities

## **NHS National Services Scotland**

2 Swinhill Avenue Canderside Toll Larkhall ML9 2QX

T:
M:
F:
E: @nhs.scot
https://www.nss.nhs.scot/

Please consider the environment before printing this email.

NHS National Services Scotland is the common name for the Common Services

Agency for the Scottish Health Service. www.nhsnss.org

This email is intended for the named recipient only. If you have received it by	
mistake, please (i) contact the sender by email reply; (ii) delete the email from your system; and (iii) do not copy the email or disclose its contents to anyone.	•

Novartis Pharmaceuticals UK Ltd. Registered in England 00119006

Registered Office: 2nd Floor, The Westworks Building, White City Place, 195 Wood Lane, London, W12 7FQ, UK

Privacy Notice: At Novartis we are committed to the responsible use of your personal data and consider privacy a very important matter. For information on how Novartis processes your personal information, please refer to our Privacy Notice(s) at novartis.co.uk/privacy-policy.

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

This email is intended for the named recipient only. If you have received it by
mistake, please (i) contact the sender by email reply; (ii) delete the email from your system; . and (iii) do not copy the email or disclose its contents to anyone.

Novartis Pharmaceuticals UK Ltd. Registered in England 00119006

Registered Office: 2nd Floor, The Westworks Building, White City Place, 195 Wood Lane, London, W12 7FQ, UK

Privacy Notice: At Novartis we are committed to the responsible use of your personal data and consider privacy a very important matter. For information on how Novartis processes your personal information, please refer to our Privacy Notice(s) at novartis.co.uk/privacy-policy.

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

This email is intended for the named recipient only. If you have received it by mistake, please (i) contact the sender by email reply; (ii) delete the email from your system; . and (iii) do not copy the email or disclose its contents to anyone.
Novartis Pharmaceuticals UK Ltd. Registered in England 00119006 Registered Office: 2nd Floor, The Westworks Building, White City Place, 195 Wood Lane, London, W12 7FQ, UK
Privacy Notice: At Novartis we are committed to the responsible use of your personal data and consider privacy a very important matter. For information on how Novartis processes your personal information, please refer to our Privacy Notice(s) at novartis.co.uk/privacy-policy.
Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.
This email is intended for the named recipient only. If you have received it by mistake, please (i) contact the sender by email reply; (ii) delete the email from your system; . and (iii) do not copy the email or disclose its contents to anyone.

Novartis Pharmaceuticals UK Ltd. Registered in England 00119006

Registered Office: 2nd Floor, The Westworks Building, White City Place, 195 Wood Lane, London, W12 7FQ, UK

Privacy Notice: At Novartis we are committed to the responsible use of your personal data and consider privacy a very important matter. For information on how Novartis

processes your personal information, please refer to our Privacy Notice(s) at novartis.co.uk/privacy-policy.

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

This email is intended for the named recipient only. If you have received it by mistake,
please (i) contact the sender by email reply; (ii) delete the email from your system; . and (iii) do not copy the email or disclose its contents to anyone.

Novartis Pharmaceuticals UK Ltd. Registered in England 00119006

Registered Office: 2nd Floor, The Westworks Building, White City Place, 195 Wood Lane, London, W12 7FQ, UK

Privacy Notice: At Novartis we are committed to the responsible use of your personal data and consider privacy a very important matter. For information on how Novartis processes your personal information, please refer to our Privacy Notice(s) at novartis.co.uk/privacy-policy.

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.